About us

Imcyse is pioneering the development of a new class of active, specific immunotherapeutics: ImotopesTM. Imcyse’s new technology platform is based on the discovery of modified synthetic peptides to block the immune processes causing immune-mediated diseases. Imcyse’s ImotopesTM  offer the possibility to cure severe chronic diseases for which there is no satisfactory therapeutic alternative. The technology can also prevent the immunogenic responses that weaken the efficiency of chronic therapies. 

Our vision is to become a major player in active specific immunotherapy for the curative treatment of autoimmune and allergic diseases.



How does Imcyse technology work ?


Latest news

Imcyse Awarded Subsidy from the Walloon Region for Neuromyelitis Optica Spectrum Disorder Study

  • Subsidy for €1.1 million over a period of 29 months to support the development of a therapeutic vaccination treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • Funds will be used to demonstrate PoC, establish the clinical relevance of the NMOSD ImotopeTM approach and lead to a Phase I clinical trial 
  • NMOSD is a rare and severe autoimmune disease of the central nervous system dominated by inflammation of the optic nerve and spinal cord with an estimated incidence between 1-2 per 100,000